Deven Choksey Research has maintained a Buy rating on Bajaj Housing Finance, setting a target price of Rs 107, implying 23% upside from the current market price of Rs 87.
News in Focus


Illegal cryptocurrency mining is draining electricity grids and funding organized crime across Southeast Asia, with Malaysia at the epicenter.

Axis Securities has maintained a Buy rating on Dabur India, though it trimmed its target price to Rs 515 from Rs 550, still implying 19% upside from the current market price of Rs 433.

ICICI Securities has maintained a Buy rating on Vedanta Aluminium Metal, holding its target price at Rs 520, implying 14% upside from the current market price of Rs 457.

Motilal Oswal has upgraded its rating on Bajaj Finance to Buy from Neutral, setting a target price of Rs 1,300, implying 23% upside from the current market price of Rs 1,054.

ICICI Securities has maintained a Buy rating on Mahindra & Mahindra, raising its target price to Rs 4,100 from Rs 4,000, implying 25% upside from the current market price of Rs 3,284.
Main Regional Stories

IDBI Capital has reiterated a Buy rating on Home First Finance Company, setting a target price of Rs 1,400, implying 19% upside from the current market price of Rs 1,181.

ICICI Securities has maintained a Buy rating on Suzlon Energy, retaining an unchanged target price of Rs 65, implying 35% upside from the current market price of Rs 48.

ICICI Securities has reiterated a Buy rating on Tata Power Company, maintaining a target price of Rs 485, implying 31% upside from the current market price of Rs 371.

ICICI Securities has maintained a Buy rating on Coforge Limited, setting a target price of Rs 1,950, implying a 17% upside from the current market price of Rs 1,669.
Melbourne: According to a top independent legal expert that the resolution of Australia’s Director of Public Prosecutions to assess the case against the apprehended Indian doctor Mohammed Haneef advised that the lawsuit was about to disintegrate
, P-Sec recommended hold rating on Thermax.
In early trades, Industrial Finance
Sharekhan Research maintained purchase rating on Sun Pharmaceutical Industries with target price of Rs 1287. At current market price Rs 965, stock valued at 21.6x FY2008E and 18.1xFY2009E fully diluted earnings.
said that it may increase term depository rates b








